A Note on the Preparation of Some 1-Phenyl-2-Nitroethanol Derivatives

Heacock, R. A.; Hutzinger, O.; Nerenberg, C.

doi:10.1139/v61-141

Cited by 9 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the appropriate reactants and making slight changes in reaction parameters [119][120][121][122][123][124] for the preparation of beta-nitroisosafrole (Fig. 3) may permit the production of 1-(3,4-methylenedioxyphenyl)-2-nitro-l-propanol.…”

Section: Precursorsmentioning

confidence: 99%

An Evaluation of the Potential for Clandestine Manufacture of 3,4-Methylenedioxyamphetamine (MDA) Analogs and Homologs

Cason

1990

Journal of Forensic Sciences

View full text Add to dashboard Cite

Encountering a novel controlled-substance analog (designer drug) has become a distinct possibility for all forensic drug laboratories. 3,4-Methylenedioxyamphetamine (MDA) in particular is a receptive parent compound for the molecular modifications which produce such homologs and analogs. The identification of these compounds, however, can prove to be an arduous task. It would be desirable to direct the focus of the identification to those compounds which are the more likely candidates for clandestine-laboratory synthesis. The process of narrowing the range of theoretical possibilities to logical choices may be enhanced by using a suitable predictive scheme. Such a predictive scheme for MDA analogs is presented based on putative Central Nervous System activity, existence or formulation of a reasonable synthesis method, and availability of the required precursors.

show abstract

Section: Precursorsmentioning

confidence: 99%

An Evaluation of the Potential for Clandestine Manufacture of 3,4-Methylenedioxyamphetamine (MDA) Analogs and Homologs

Cason

1990

Journal of Forensic Sciences

View full text Add to dashboard Cite

show abstract

Synthesis of a 2,5‐diaryloxazoline as a potential platelet‐activating factor antagonist

Peet¹,

Burkhart²,

Broersma³

et al. 1994

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

2,5‐Bis‐(3,4,5‐trimethoxyphenyl)‐2‐oxazoline (5, MDL 100,270) was designed as a potential platelet‐activating factor (PAF) antagonist on the basis of computer modeling comparison studies with known PAF antagonists. An efficient, four‐step synthesis of oxazoline 5 was developed, starting from 3,4,5‐trimethoxybenzaldehyde (6). Oxazoline 5 was found to inhibit the PAF‐induced aggregation of human platelets with an IC50 value of 708 μM.

show abstract